Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years

Summary

This is a A Phase III, Open label, Multicenter, Single Arm Study to assess the Safety, Tolerability and Immunogenicity of VLA2001 in volunteers aged ≥ 56 years. Approximately 300 participants are enrolled in a non-randomized manner.

Timeline

Start

2021-08-09

Primary completion

2021-11-10

Completion

2022-11-18

Drugs

Indications